Determining the effectiveness of Ivermectin in the treatment of Covid-19 infection in hospitalized patients in Mazandaran educational hospitals in 2020
Clinical trial with control group, with parallel groups, double-blind, randomized, phase 3 on 60 patients. Study patients are divided into two groups by simple randomization method with random number table. The control group will receive the standard treatment and the intervention group will receive a single dose of Ivermectin in addition to the standard treatment.
Settings and conduct:
Patients with coronavirus hospitalized in Mazandaran educational hospitals are randomly divided into two groups of intervention and control.
The present study is double-blind so that patients and the care provider will be unaware of how the intervention and control group is allocated.
Participants/Inclusion and exclusion criteria:
Patients with suspected Covid-19 hospitalized over the age of 5 years and weight more than 15 kg will be included in the study if they are satisfied.
In the intervention group, along with the standard drugs of the national protocol for the treatment of coronavirus infection, a single dose of Ivermectin 3 mg oral tablet with a dose of 0.2 mg/kg of Tadbir Kala Jam Company will be used according to the following : weight 15-24, 3 mg ; Weight 25-3, 6 mg; Weight 36-50, 9 mg; Weight 51-80, 12 mg and weight over 80, 0.2 mg/kg
Main outcome variables:
Clinical symptoms including fever, chills, sore throat, cough, shortness of breath, decreased appetite, abdominal pain, dizziness, insomnia, itching, joint pain, joint swelling, headache, nausea, vomiting, diarrhea, malaise, conjunctivitis, tachycardia, wheezing, rhonchus, retraction, hypotension, rash, other symptoms, and respiratory rate and O2 saturation will be recorded in first, second, third, fourth, fifth, sixth, seventh day.